Recombinant Human cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A)

1. childhood onset of chorea with normal cognition and striatal hyperintensities should prompt further evaluation beyond benign hereditary chorea and heterozygous or homozygous mutations in PDE10A can cause such a phenotype. More number of cases needs to be identified before a definite phenotype genotype correlation can be made in such cases. PMID: 29130591
2. Results indicate that aging is associated with a considerable physiological reduction of the availability of phosphodiesterase 10A enzyme enzyme in the striatum. PMID: 28254508
3. Collectively, these findings highlight a novel thermoregulatory role for PDE10A in mouse and human adipocytes and promote PDE10A inhibitors as promising candidates for the treatment of obesity and diabetes. PMID: 27247380
4. The method proposed for quantification of [(11)C]Lu AE92686 binding in applied studies in NHP is based on 63 min PET data and SRTM with cerebellum as a reference region. The study supports that [(11)C]Lu AE92686 can be used for PET examinations of PDE10A binding also in substantia nigra. PMID: 27817159
5. Studied what regions of the PDE10A gene are transcribed in human putamen and caudate nucleus brain tissue, two sub-regions of the striatum. Surprisingly, twelve novel transcripts were detected, of which three were predicted to be translated into PDE10A proteins with unique N-termini.studies show that there is much more transcript diversity within the PDE10A gene region than initially believed. PMID: 28042091
6. The PDE10A gene is currently known to be comprised of 23 exons26 and maps to chromosome 6q26,17, 18 a region previously associated with bipolar disorder. PMID: 26905414
7. germline PDE10A mutations associated with hyperkinetic movement disorder PMID: 27058446
8. We have demonstrated that de novo dominant mutations in PDE10A are the cause of a unique movement disorder characterized by benign childhood-onset chorea and typical MRI abnormalities of the striatum. PMID: 27058447
9. cGMP PDE isozymes, PDE5 and 10, are elevated in colon tumor cells compared with normal colonocytes, and inhibitors and siRNAs can selectively suppress colon tumor cell growth PMID: 26299804
10. Longitudinal data in a cohort of patients with early Huntington disease found PDE10 to be a useful biomarker of disease progression. PMID: 26802091
11. Lu AF33241 represents a novel PDE2A/PDE10A inhibitor tool which can penetrate the blood brain barrier. PMID: 25941078
12. Data provide evidence that PDE10 is involved in colon tumorigenesis and show its overexpression in colon tumor cells compared with colonocytes. PMID: 24704829
13. PDE10A activity in medium spiny neurons in Huntington's disease might still be high in critical subcellular compartments, despite the overall striatal PDE10A decrease measured using positron-emission tomography. PMID: 24353339
14. HPRT-deficiency alters cAMP/PKA signaling pathway, which is in part due to the increased of PDE10A expression and activi PMID: 23691025
15. The present study is the first to demonstrate a central role of PDE10A in progressive pulmonary vascular remodeling. PMID: 21494592
16. The data of this results supported a model whereby PDE10A trafficking and localization can be regulated in response to local fluctuations in cAMP levels. PMID: 20610737
17. analysis of functional chimeras of the phosphodiesterase 5 and 10 tandem GAF domains PMID: 18635550
18. Binding of cyclic nucleotides to phosphodiesterase 10A and 11A GAF domains does not stimulate catalytic activity. PMID: 19689430

Show More

Hide All

HGNC: 8772

OMIM: 610652

KEGG: hsa:10846

STRING: 9606.ENSP00000438284

UniGene: Hs.348762